479 related articles for article (PubMed ID: 12015841)
21. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas.
Johannessen AL; Torp SH
Pathol Oncol Res; 2006; 12(3):143-7. PubMed ID: 16998593
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of MIB-1 staining indices of gliomas measured by NIH Image analysis program and conventional manual cell counting method.
Amin MR; Kurosaki M; Watanabe T; Tanaka S; Hori T
Neurol Res; 2000 Jul; 22(5):495-500. PubMed ID: 10935223
[TBL] [Abstract][Full Text] [Related]
23. Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.
Geiger KD; Stoldt P; Schlote W; Derouiche A
Am J Pathol; 2000 Dec; 157(6):1785-93. PubMed ID: 11106550
[TBL] [Abstract][Full Text] [Related]
24. Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods.
Hsu CY; Ho DM; Yang CF; Chiang H
Mod Pathol; 2003 Sep; 16(9):951-7. PubMed ID: 13679460
[TBL] [Abstract][Full Text] [Related]
25. Prognostic relevance of MIB-1 immunoreactivity, S-phase fraction, 5-bromo-2'-deoxyuridine labeling indices, and mitotic figures in gliomas.
Struikmans H; Rutgers DH; Jansen GH; Dullens HF; Oosten L; Tulleken CA; van der Tweel I; Battermann JJ
Radiat Oncol Investig; 1999; 7(4):243-8. PubMed ID: 10492165
[TBL] [Abstract][Full Text] [Related]
26. Relationship between Ki-67 labeling index and survival in high-grade glioma patients treated after surgery with tamoxifen.
Mastronardi L; Guiducci A; Puzzilli F; Ruggeri A
J Neurosurg Sci; 1999 Dec; 43(4):263-70. PubMed ID: 10864388
[TBL] [Abstract][Full Text] [Related]
27. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
[TBL] [Abstract][Full Text] [Related]
28. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas.
Hsu DW; Louis DN; Efird JT; Hedley-Whyte ET
J Neuropathol Exp Neurol; 1997 Aug; 56(8):857-65. PubMed ID: 9258255
[TBL] [Abstract][Full Text] [Related]
29. Association between Ki-67 Labeling index and Histopathological Grading of Glioma in Indonesian Population.
Theresia E; Malueka RG; Pranacipta S; Kameswari B; Dananjoyo K; Asmedi A; Wicaksono AS; Hartanto RA; Dwianingsih EK
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1063-1068. PubMed ID: 32334471
[TBL] [Abstract][Full Text] [Related]
30. Expression of high-mobility group AT-hook protein 2 and its prognostic significance in malignant gliomas.
Liu B; Pang B; Hou X; Fan H; Liang N; Zheng S; Feng B; Liu W; Guo H; Xu S; Pang Q
Hum Pathol; 2014 Aug; 45(8):1752-8. PubMed ID: 24935062
[TBL] [Abstract][Full Text] [Related]
31. The proliferative potential of the pilocytic astrocytoma: the relation between MIB-1 labeling and clinical and neuro-radiological follow-up.
Dirven CM; Koudstaal J; Mooij JJ; Molenaar WM
J Neurooncol; 1998 Mar; 37(1):9-16. PubMed ID: 9525833
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.
Abdulrauf SI; Edvardsen K; Ho KL; Yang XY; Rock JP; Rosenblum ML
J Neurosurg; 1998 Mar; 88(3):513-20. PubMed ID: 9488306
[TBL] [Abstract][Full Text] [Related]
33. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
Shono T; Tofilon PJ; Bruner JM; Owolabi O; Lang FF
Cancer Res; 2001 Jun; 61(11):4375-81. PubMed ID: 11389063
[TBL] [Abstract][Full Text] [Related]
34. Regional differences in bromodeoxyuridine uptake, expression of Ki-67 protein, and nucleolar organizer region counts in glioblastoma multiforme.
Onda K; Davis RL; Wilson CB; Hoshino T
Acta Neuropathol; 1994; 87(6):586-93. PubMed ID: 8091951
[TBL] [Abstract][Full Text] [Related]
35. Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors.
Grzybicki DM; Liu Y; Moore SA; Brown HG; Silverman JF; D'Amico F; Raab SS
Cancer; 2001 Nov; 92(10):2720-6. PubMed ID: 11745208
[TBL] [Abstract][Full Text] [Related]
36. Increased microglia proliferation separates pilocytic astrocytomas from diffuse astrocytomas: a double labeling study.
Klein R; Roggendorf W
Acta Neuropathol; 2001 Mar; 101(3):245-8. PubMed ID: 11307624
[TBL] [Abstract][Full Text] [Related]
37. Proliferative potential of malignant glioma cells before and after interstitial brachytherapy.
Kunishio K; Matsumoto K; Higashi H; Adachi H; Tamiya T; Furuta T; Ohmoto T
Neurol Med Chir (Tokyo); 1999 May; 39(5):341-9. PubMed ID: 10481436
[TBL] [Abstract][Full Text] [Related]
38. The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study.
Dropcho EJ; Soong SJ
Neurology; 1996 Sep; 47(3):684-90. PubMed ID: 8797465
[TBL] [Abstract][Full Text] [Related]
39. Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors.
Nishizaki T; Orita T; Furutani Y; Ikeyama Y; Aoki H; Sasaki K
J Neurosurg; 1989 Mar; 70(3):379-84. PubMed ID: 2536805
[TBL] [Abstract][Full Text] [Related]
40. Endothelial nitric oxide synthase expression in tumor vasculature is correlated with malignancy in human supratentorial astrocytic tumors.
Iwata S; Nakagawa K; Harada H; Oka Y; Kumon Y; Sakaki S
Neurosurgery; 1999 Jul; 45(1):24-8; discussion 29. PubMed ID: 10414562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
